



# HIP FRACTURE PATIENTS AND DOACs



The direct oral anticoagulant (DOAC) sprint audit aimed to describe the management of hip fracture patients taking DOACs. In 2024, 31 facilities across Australia and New Zealand (ANZ) completed the audit for a 2 month period and provided information on 1,043 hip fracture patients.

## Australia

24 facilities



5/24 facilities

Protocol for the peri-operative management of DOACs

5/24 facilities

Measurement of pre-operative DOAC levels

840 patients

## New Zealand

7 facilities




7/7 facilities

2/7 facilities



203 patients

### Anticoagulants/antiplatelets on admission (%)



### Before surgery

DOAC reversal agent administered for patients on apixaban or rivaroxaban (%) \*

Australia



3.5%

New Zealand



0.0%

DOAC reversal agent administered for patients on dabigatran (%)



0.0%



58.3%

\*New Zealand does not have access to apixaban

### Time to surgery (%)

DOAC

No DOACs



### After surgery


#### Blood transfusion up to 48h after surgery (%)

DOAC

No DOACs



#### Number of units for patients who received a blood transfusion (%)



#### Time to recommence DOAC after surgery (%)

Australia

New Zealand

